MATINAS BIOPHARMA HOLDINGS INC (MTNB)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$0.18+0.55%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MTNB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -89.7% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
MTNB — legal / regulatory event
Dated 2026-09-04
of the Current Reports on Form 8-K filed with the Securities and Exchange Commission on April 3, 2026 and June 26, 2026, the Company also received written notices from the NYSE American indicating that the Company was not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and 1003(a)(iii) of the Company Guide. Section 1003(a)(ii) requires a company to have stockholders’ equity of at least $4.0 million if it has reported losses from continuing operations and/o…
Why it matters: Better operating income shows the company is making progress. It means fewer losses.
Supportive ifQ2 2026 operating income shows improvement from -$1.936M in Q1 2026.
Worry ifQ2 2026 operating income worsens or remains at -$1.936M or worse.
Why it matters: The company faces a risk of delisting due to non-compliance. Progress here is crucial for stability.
Worry ifManagement announces a plan to meet NYSE compliance standards by the next quarter.
Less concerning ifNo progress has been reported. This leads to more notices from NYSE American.
Why it matters: Approval is crucial for Matinas to maintain its listing on the NYSE American. Failure to comply could lead to delisting.
Worry ifThe NYSE American agrees with Matinas' plan. They must meet the deadline by October 2, 2027.
Less concerning ifThe NYSE American rejects the plan or Matinas fails to show progress by the deadline.
Why it matters: This sale could give Matinas quick cash and future royalties, affecting its finances.
Supportive ifThe sale to Azurity is complete. They received the $4.0 million upfront payment.
Worry ifFailure to complete the sale or delays in receiving the upfront payment.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$370 on $10,000 · ±3.7% | How much price usually moves either way. |
| Bad day | $1,085 loss on $10,000 · 10.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,135 loss on $10,000 · 91.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.